舒洛地昔治疗中国患者特发性膜性肾病的疗效：一项荟萃分析。
Efficacy of sulodexide in treating idiopathic membranous nephropathy among Chinese patients: a meta-analysis.
作者信息
Wang Tao, Xu Jiwen, Sun Yiming, Liu Li, Li Yue, Cai Xiaojun, Chen Ming, Fang Yingying
机构信息
Department of Endocrinology, Heilongjiang Academy of Traditional Chinese Medicine Harbin, Heilongjiang, China.
School of Basic Medical Sciences, Heilongjiang University of Chinese Medicine Harbin, Heilongjiang, China.
出版信息
Am J Transl Res. 2024 Jul 15;16(7):2756-2764. doi: 10.62347/RNLQ2888. eCollection 2024.
OBJECTIVE
To evaluate the efficacy of Sulodexide in treating idiopathic membranous nephropathy (IMN) in the Chinese population.
METHODS
We systematically reviewed all eligible randomized clinical trials (RCTs) conducted in China that investigated the effects of Sulodexide on IMN. Three RCTs published between 2013 and 2022 were included, encompassing a total of 146 patients. The primary outcomes evaluated were changes in urine total protein (UTP), serum albumin (ALB), cholesterol (CHOL), and fibrinogen (FIB) levels.
RESULTS
Statistically significant differences were observed in the Sulodexide treatment group compared to the control group for the following parameters: reduction in UTP and CHOL, increase in ALB, and reduction in FIB levels.
CONCLUSION
Sulodexide, when combined with conventional therapy, effectively reduces UTP and CHOL levels, decreases FIB levels, and increases ALB in Chinese patients with IMN.
目的
评估舒洛地昔在中国人群中治疗特发性膜性肾病（IMN）的疗效。
方法
我们系统回顾了在中国进行的所有符合条件的随机临床试验（RCT），这些试验研究了舒洛地昔对IMN的影响。纳入了2013年至2022年间发表的三项RCT，共涉及146例患者。评估的主要结局指标为尿总蛋白（UTP）、血清白蛋白（ALB）、胆固醇（CHOL）和纤维蛋白原（FIB）水平的变化。
结果
与对照组相比，舒洛地昔治疗组在以下参数方面观察到统计学显著差异：UTP和CHOL降低、ALB升高以及FIB水平降低。
结论
在中国IMN患者中，舒洛地昔与传统疗法联合使用时，可有效降低UTP和CHOL水平，降低FIB水平，并提高ALB水平。
Zotero 插件